Can levetiracetam (Keppra) cause rage-like behavior and how should it be managed?

Levetiracetam-Associated Behavioral Disturbances ("Keppra Rage")

Levetiracetam can cause significant behavioral adverse effects including aggression, irritability, rage, and suicidal ideation in 5–15% of patients, and these symptoms require immediate dose reduction or discontinuation of the medication. 1, 2

Recognition and Clinical Features

Levetiracetam-induced behavioral disturbances manifest as:

• Aggression and rage: Characterized by seething rage, uncontrollable anger, fits of fury, and violent behavior toward others 3
• Irritability and agitation: Reported in 5–6.3% of patients in controlled trials 1
• Mood disturbances: Depression, mood swings, tearfulness, and negativism occurring in 6.7–12.7% of patients 1
• Suicidal ideation: Rare but serious, with documented cases of suicide attempts 3
• Timing: Symptoms typically emerge within the first week of initiating therapy or following dose increases 4, 3

The FDA label explicitly warns that behavioral abnormalities (aggression, irritability, anger, aggressive behavior) have been reported since market approval, with an overall estimated risk of 12–15% 1, 2.

High-Risk Populations

Certain patient groups face substantially elevated risk and require heightened monitoring:

• Learning-disabled individuals: Higher susceptibility to behavioral adverse effects 2
• Prior psychiatric history: Patients with pre-existing mood disorders, anxiety, or psychotic disturbances are at increased risk 2, 5
• Symptomatic generalized epilepsy: This population demonstrates higher rates of behavioral complications 2
• Pediatric patients: Children and adolescents show increased ADHD symptoms and oppositional defiant disorder features, with one study documenting a rise from 16% to 48% meeting ADHD+ODD criteria after levetiracetam initiation 6
• Autism spectrum disorder: A study in children with autism found aggression as a significant side effect when levetiracetam was used at 20–30 mg/kg/day 7

Immediate Management Algorithm

Step 1: Confirm Levetiracetam as the Causative Agent

• Temporal relationship: Verify that behavioral changes began within days to weeks of starting levetiracetam or increasing the dose 4, 3
• Naranjo probability scale: Both documented cases of levetiracetam-induced rage scored 8 (probable adverse drug reaction) 3
• Rechallenge phenomenon: Symptoms resolve with discontinuation and recur with reintroduction (though rechallenge is not recommended due to safety concerns) 3

Step 2: Discontinue or Reduce Levetiracetam Immediately

For severe behavioral disturbances (rage, violence, suicidal ideation):

• Complete discontinuation is required immediately 3
• Taper gradually over 1–2 weeks to minimize seizure risk, as abrupt withdrawal can increase seizure frequency 1
• Symptoms typically resolve rapidly (within days) after discontinuation 4, 3

For mild-to-moderate irritability or mood changes:

• Dose reduction may be attempted first, as one study showed 1.7% of patients required dose reduction for somnolence without full discontinuation 1
• If symptoms persist despite dose reduction, proceed to complete discontinuation 1

Step 3: Substitute Alternative Antiepileptic Agent

Select an alternative based on seizure type and patient factors:

• Valproate 20–30 mg/kg IV for acute seizures or oral maintenance dosing; avoid in women of childbearing potential due to teratogenicity 8
• Lamotrigine: Requires slow titration over several weeks to reduce rash risk; suitable for outpatient transition 8
• Lacosamide: Available in IV formulation for acute management with favorable tolerability profile (dizziness, headache, somnolence) 8
• Phenytoin/fosphenytoin: Traditional option with 84% efficacy but 12% hypotension risk requiring cardiac monitoring 8

Step 4: Psychiatric Evaluation and Support

• Urgent psychiatric consultation for patients with suicidal ideation or severe aggression 3
• Safety planning: Remove access to weapons or means of self-harm in patients with suicidal thoughts 3
• Caregiver education: Instruct family members to monitor for early warning signs of behavioral deterioration 3

Prevention Strategies

Minimize risk through proactive screening and monitoring:

• Pre-treatment psychiatric assessment: Screen for prior mood disorders, anxiety, psychosis, or behavioral problems before initiating levetiracetam 3
• Slow dose titration: Gradual increases may reduce the incidence of behavioral adverse effects 4
• Close monitoring: Caregivers and physicians should watch for early features of irritability, anger, or mood changes during the first weeks of therapy 3
• Patient counseling: Inform patients and families about the 12–15% risk of behavioral adverse effects and instruct them to report symptoms immediately 2

Special Considerations

Autism spectrum disorder: In children with autism, levetiracetam at 20–30 mg/kg/day showed no significant difference in global functioning or irritability compared to placebo in one trial, but aggression was noted as a side effect 7. Consider alternative agents in this population.

Refractory epilepsy: When levetiracetam is the only effective agent for seizure control, the risk-benefit ratio must be carefully weighed. However, documented cases show that behavioral adverse effects can be life-threatening (violence, suicide attempts), and discontinuation is often necessary despite seizure control 3.

Rechallenge: Do not attempt rechallenge in patients who have experienced severe behavioral disturbances, as symptoms reliably recur and may worsen 3.

Common Pitfalls

• Attributing symptoms to seizure disorder: Behavioral changes may be mistakenly attributed to the underlying epilepsy rather than the medication 3
• Delaying discontinuation: Waiting to see if symptoms resolve spontaneously can lead to escalation of violence or self-harm 3
• Inadequate monitoring: Failure to educate caregivers about warning signs results in delayed recognition 3
• Abrupt withdrawal: Stopping levetiracetam suddenly without tapering increases seizure risk 1